Strong US portfolio to drive revenue growth for Aurobindo Pharma

Margins expected to improve on product mix and volume growth

Aurobindo’s June quarter performance was in line with Street estimates, led by a steady growth in its US business. The geography, which accounts for 52 per cent of its revenues, posted a 16 per cent growth in revenue. 

Higher growth in oral solids and dietary supplements, which account for 80 per cent of the total revenue, bodes well for the firm. Though US revenues were better than estimates, growth on a sequential basis came in just under 4 per cent, pegged back by elective surgeries, which were postponed because of the Covid-19 pandemic. 

Revenue from the injectable segment, which accounts for 19